The clinical ramifications were equally profound, prompting use of pulsatile GnRH therapies to treat hypothalamic hypo‐gonadotropism, and non‐pulsatile GnRH agonist treatments to suppress gonadotropin secretions in precocious puberty or prostate cancer therapies. Here, GNRH1 is linked to prostate cancer.